ALK and non-small cell lung carcinoma: The following inclusion criteria were used to screen articles found: (1) studies published in the English language; (2) human studies; (3) randomized controlled trials and cohort studies; (4) articles published in the last 10 years; (5) articles including males and females above 18 years of age, worldwide; and (6) randomized clinical trials and cohort studies that assessed the effects of crizotinib in ALK-mutated NSCLC.